Zobrazeno 1 - 10
of 32
pro vyhledávání: '"David Laidley"'
Autor:
Lucas C. Mendez, Aneesh Dhar, David Laidley, Madeleine Moussa, Jose A. Gomez, Joseph Chin, T-Y Lee, Jonathan D. Thiessen, Douglas Hoover, Kathleen Surrey, Joelle Helou, Vikram Velker, Rohann J. Correa, David D’Souza, Jane Bayani, Glenn Bauman
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background Isolated local failure (ILF) can occur in patients who initially receive definitive radiation therapy for prostate cancer. Salvage therapy for ILF includes high dose rate (HDR) brachytherapy. Prostate Specific Membrane Antigen (PS
Externí odkaz:
https://doaj.org/article/719ea29aef334e5884645ab05b804387
Autor:
Wei Liu, Andrew Loblaw, David Laidley, Hatim Fakir, Lucas Mendez, Melanie Davidson, Zahra Kassam, Ting-Yim Lee, Aaron Ward, Jonathan Thiessen, Jane Bayani, John Conyngham, Laura Bailey, Joseph D. Andrews, Glenn Bauman
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Advances in imaging have changed prostate radiotherapy through improved biochemical control from focal boost and improved detection of recurrence. These advances are reviewed in the context of prostate stereotactic body radiation therapy (SBRT) and t
Externí odkaz:
https://doaj.org/article/a086dc0182be476da5bdecb8f6dc5f2e
Autor:
Olfat Kamel Hasan, Sarah De Brabandere, Irina Rachinsky, David Laidley, Danielle MacNeil, Stan Van Uum
Publikováno v:
Journal of Thyroid Research, Vol 2020 (2020)
Introduction. Differentiated thyroid cancer (DTC) has an overall excellent prognosis. Patients who develop recurrent disease have a more unfavorable disease course than those with no recurrence. Higher recurrence rates are seen with incomplete surgic
Externí odkaz:
https://doaj.org/article/6a628744a554474cb1a4dab9611a201b
Autor:
Robert H. Reid, Mina Swiha, Daniele Wiseman, Alireza Khatami, Amol Mujoomdar, Golmehr Sistani, Rami M Abazid, Jonathan Romsa, Duncan E. K. Sutherland, David Laidley
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose 177Lu-Dotatate is an emerging treatment modality for patients with unresectable or metastatic well-differentiated NETs. This study examines survival predictors in patients who received 177Lu-Dotatate. Methods A retrospective single-center rev
Autor:
Robert Z. Stodilka, James Warrington, Khaled Ahmed, Cigdem Akincioglu, Jonathan Romsa, Aashish Goela, David Laidley, Duncan E. K. Sutherland, Rami M Abazid, William C. Vezina
Publikováno v:
Journal of Cardiovascular Computed Tomography. 15:e98-e100
Autor:
Ur Metser, Rosalyn A. Juergens, Rebecca Wong, David Laidley, Zhihui Amy Liu, Claudia Ortega, Joshua D. Schaefferkoetter, Sten Myrehaug, Reut Anconina, Patrick Veit-Haibach
Publikováno v:
Journal of Nuclear Medicine. 62:1406-1414
PURPOSE: To determine whether quantitative PET parameters on baseline 68Ga-DOTATATE PET/CT (bPET) and interim PET (iPET) performed prior to second cycle of therapy are predictive of therapy response and progression free survival (PFS). PATIENTS & MET
Autor:
Robert H. Reid, Elena V Tsvetkova, Duncan E. K. Sutherland, David Laidley, Alireza Khatami, Amol Mujoomdar, Daniele Wiseman, Golmehr Sistani
Publikováno v:
Current Oncology
Volume 28
Issue 1
Pages 15-127
Current Oncology, Vol 28, Iss 15, Pp 115-127 (2021)
Volume 28
Issue 1
Pages 15-127
Current Oncology, Vol 28, Iss 15, Pp 115-127 (2021)
Peptide receptor radionuclide therapy (PRRT) has been recently established as a treatment option for progressive gastro-entero-pancreatic neuroendocrine tumors (NETs) including four 200 mCi induction cycles. The purpose of this phase 2 trial is to ex
Autor:
James Warrington, Robert Z. Stodilka, Cigdem Akincioglu, David Laidley, Turki Alkordy, Jonathan Romsa, William C. Vezina, Shengnan Wang, Stephen Nelli, Martina Price
Publikováno v:
Journal of Nuclear Cardiology. 28:760-762
Autor:
Rosalyn A. Juergens, Raimond Wong, James Brierley, Sten Myrehaug, Z. Liu, K Lajkosz, David Laidley
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:e81-e82
Purpose/objective(s) The objective of this report is to explore the relationship between response to therapy and quality of life experience. Materials/methods Key study eligibility criteria include progressive metastatic NET, Ki67 index ≤30%, ECOG
Autor:
David Laidley, Golmehr Sistani, Glenn Bauman, Ur Metser, Stephen E. Pautler, Katherine Zukotynski
Publikováno v:
Medical Biophysics Publications
Can Urol Assoc J
Can Urol Assoc J
Prostate cancer is the most commonly diagnosed cancer, except for skin cancer, and the second leading cause of cancer-related death among Canadian males.1 Recurrence is not uncommon, despite local therapies, such as radical prostatectomy, radiation,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4432aa6dc86f9e79901a94b2b7f9fb3c
https://ir.lib.uwo.ca/biophysicspub/475
https://ir.lib.uwo.ca/biophysicspub/475